Immunomodulation in stable renal transplant recipients with concomitant tacrolimus and sirolimus therapy

Medical Immunology

Volumn 1, Issue , 2002, Pages

  Khanna, Ashwani ^a   Plummer, Matthew ^a   Bromberek, Katherine ^a   Woodliff, Jeffrey ^a   Hariharan, Sundaram ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLIN E; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN P21; RAPAMYCIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SEQUENCE; HUMAN; IMMUNOMODULATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 2942585635     PISSN: 14769433     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-9433-1-3     Document Type: Article

References (29)

1. Kahan BD: Cyclosporine. N Engl J Med 1989, 321:1725-1728
2. Plosker GL, Foster RH: Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000, 59:323-389
3. Sehgal SN: Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998, 31:335-340
4. Trotter JF, Wachs ME, Trouillot TE, Bak T, Kugelmas M, Everson G, Kam I: Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl 2001, 7:401-408
5. Dominguez J, Mahalati K, Kiberd B, McAlister VC, MacDonald AS: Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 2000, 70:1244-1247
6. Meier-Kriesche HU, Kaplan B: Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations. Clin Ther 2000, 22:B93-100
7. Andoh TF, Burdmann EA, Fransechini N, Houghton DC, Bennett WM: Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 1996, 50:1110-1117
8. Qi S, Xu D, Peng J, Vu MD, Wu J, Bekersky I, Fitzsimmons WE, Peets J, Sehgal S, Daloze P, Chen H: Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. Transplantation 2000, 69:1275-1283
9. Vu MD, Qi S, Xu D, Wu J, Fitzsimmons WE, Sehgal SN, Dumont L, Busque S, Daloze P, Chen H: Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997, 64:1853-1856
10. McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS: Sirolimus-tacrolimus combination immunosuppression. Lancet 2000, 355:376-377
11. Khanna AK: Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation 2000, 70:690-694
12. Khanna A, Hosenpud J: Cyclosporine induces the expression of the cyclin inhibitor p21. Transplantation 1999, 67:1262-1268
13. Haegeman G, Content J, Volckaert G, Derynck R, Tavernier J, Fiers W: Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts. Eur J Biochem 1986, 159:625-632
14. Vieira P, de Waal-Malefyt R, Dang MN, Johnson KE, Kastelein R, Fiorentino DF, deVries JE, Roncarolo MG, Mosmann TR, Moore KW: Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 1991, 88:1172-1176
15. Gray PW, Leung DW, Pennica D, Yelverton E, Najarian R, Simonsen CC, Derynck R, Sherwood PJ, Wallace DM, Berger SL, Levinson AD, Goeddel DV: Expression of human immune interferon cDNA in E. coli and monkey cells Nature 1982, 295:503-508
16. Koff A, Cross F, Fisher A, Schumacher J, Leguellec K, Philippe M, Roberts JM: Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family Cell 1991, 66:1217-1228
17. Horne MC, Goolsby GL, Donaldson KL, Tran D, Neubauer M, Wahl AF: Cyclin G1 and cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression J Biol Chem 1996, 271:6050-6061
18. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV: Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984, 312:724-729
19. Qi S, Xu D, Peng J, Liu D, Chen H: Synergistic effect of rapamycin and cyclosporine in prevention of acute kidney allograft rejection in the mouse. Microsurgery 1999, 19:344-347
20. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT: Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998, 66:1040-1046
21. Khanna A, Cairns V, Becker CG, Hosenpud JD: Transforming Growth Factor-beta (TGF-β) mimics and anti-TGF-β antibody abrogates the in-vivo effects of Cyclosporine: demonstration of a direct role of TGF-β in immunosuppression and nephrotoxicity of CsA. Transplantation 1999, 67:882-888
22. Khanna A, Cairns V, Hosenpud JD: Tacrolimus induces increased expression of transforming growth factor-beta in lymphoid and non-lymphoid cells. Transplantation 1999, 67:614-619
23. Itano H, Mora BN, Zhang W, Ritter JH, McCarthy TJ, Yew NS, Mohanakumar T, Patterson GA: Lipid-mediated ex vivo gene transfer of viral interleukin 10 in rat lung allotransplantation. J Thorac Cardiovasc Surg 2001, 122:29-38
24. Zuo Z, Wang C, Carpenter D, Okada Y, Nicolaidou E, Toyoda M, Trento A, Jordan SC: Prolongation of allograft survival with viral IL-10 transfection in a highly histoincompatible model of rat heart allograft rejection. Transplantation 2001, 71:686-691
25. Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR, Morris PJ, Powrie F, Wood KJ: IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001, 166:3789-3796
26. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK: IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998, 101:311-320
27. La Flamme AC, Pearce EJ: The absence of IL-6 does not affect Th2 cell development in vivo, but does lead to impaired proliferation, IL-2 receptor expression, and B cell responses. J Immunol 1999, 162:5829-5837
28. Newstead CG, Lamb WR, Brenchley PE, Short CD: Serum and urine IL-6 and TNF-alpha in renal transplant recipients with graft dysfunction. Transplantation 1993, 56:831-835
29. Jain S, Furness PN, Nicholson ML: The role of transforming growth factor beta in chronic renal allograft nephropathy. Transplantation 2000, 69:1759-1766